Latest News

Border zone lifetime gradient correlated with growth rate over 5 years

Real-world data support EndoArt as donor-independent option in high-risk patients

Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.

Varicella vaccine drove the largest risk reduction in a 5-vaccine, multi-million-patient analysis

Biologic therapies linked to high remission rates over 2-year follow-up

In this Q&A, Dipanjan Pan, PhD, breaks down the science behind the COSMIC tear biosensor platform and what it will take to bring it to clinical use.

What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape

Researchers identify microbial shifts tied to corneal disease history

Deeper anterior chamber depth and shorter disease course predicted better surgical outcomes

The FDA has granted priority review to satralizumab for thyroid eye disease, with a PDUFA date of October 15, 2026, based on phase 3 SatraGO trial data.

Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.

Three cases illustrate how next-generation anti-VEGF agents are extending treatment intervals and improving durability across retinal vascular disease.

The trial over-enrolled and finished approximately 4 months ahead of initial projections, with 52-week topline data now expected in the second half of 2027.